<DOC>
	<DOCNO>NCT01764256</DOCNO>
	<brief_summary>This study evaluate 3 dos new vaccine rotavirus infection healthy adult volunteer determine safe immune system healthy adult respond vaccine .</brief_summary>
	<brief_title>A Phase 1 Dose Escalation Study Examine Safety P2-VP8 Rotavirus Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Rotavirus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>A qualified volunteer must : 1 . Healthy male female 18 45 ( inclusive ) year age time enrollment . 2 . Willing able give inform consent must pass test comprehension &gt; 70 % correct within two attempt . 3 . If female childbearing potential , breastfeed pregnant ( base negative serum pregnancy test screen negative urine pregnancy test 24 hour prior first injection ) , plan avoid pregnancy least 4 week last injection , willing use adequate method contraception consistently repeat pregnancy test prior second third injection . 4 . Willing comply study restriction study schedule ( evidence sign informed consent form [ ICF ] assessment PI designee ) . 5 . Able willing contact telephone text , willing study staff record telephone voice text message need . A qualified volunteer must : 1 . Have receive investigational product 30 day prior randomization . 2 . Intend receive another investigational product study . 3 . Have contraindication parenteral injection ( e.g. , history bleed disorder ) . 4 . Have previously receive marketed investigational rotavirus vaccine . 5 . Have history severe local systemic reaction vaccine . 6 . Have history recurrent urticaria unknown cause . 7 . Have history allergic infusion reaction severe ( e.g. , anaphylactic anaphylactoid ) , generalize ( e.g. , drug rash , urticaria , angioedema ) , opinion PI , significantly increase risk severe local systemic reaction investigative vaccine . 8 . Have history reaction vaccine , opinion PI , significantly increase risk severe reaction investigative vaccine . 9 . Have receive vaccine within 4 week prior randomization planned vaccination Day 84 . 10 . Have receive blood product immunomodulating agent ( e.g. , immunoglobulin , interferon , growth factor ) within 12 week prior randomization . 11 . Have receive immunosuppressive medication ( e.g. , prolong use systemic corticosteroid cytotoxic agent ) within 24 week prior randomization . Eligible short course ( â‰¤10 day ) systemic corticosteroid conclude 2 week prior randomization , use inhale corticosteroid asthma , use topical corticosteroid skin condition . 12 . Have history clinically significant ( opinion PI ) immunosuppressive autoimmune condition . 13 . Anticipate need administration blood product , immunosuppressive ( e.g. , systemic corticosteroid ) , immunomodulatory treatment study . 14 . Have history malignancy , exclude basal cell carcinoma . 15 . Have Diabetes Mellitus Type I II . 16 . Have positive test HIV1 , HBsAg antiHepC . 17 . Have significant abnormality screen laboratory test result clinical assessment determine PI PI consultation Sponsor 's medical officer . * 18 . Have abnormal vital sign deem clinically relevant PI . * 19 . Evidence current recent ( within past 12 month ) excessive alcohol consumption drug dependence . 20 . Have condition hand , arm relate lymph node may confound postdose assessment . 21 . Have condition ( medical , psychiatric behavioral ) , opinion PI , would increase volunteer 's health risk study participation would increase risk achieve study 's objective</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>rotavirus</keyword>
	<keyword>vaccine</keyword>
</DOC>